Safety of Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes and CKD
- Design
- Retrospective cohort
- Drugs
- Class unspecified
- Assessment
- Not yet reviewed by a person · added Oct 18, 2026
This study was added automatically and has not been reviewed. Until it is, the collection publishes no population match, weight-loss explanation, study tier, findings, population or funding details for it: a check of automatically extracted details found too many errors to show them as fact. The abstract below is the source as retrieved.
01Source
The source, as retrieved
Abstract
[RATIONALE & OBJECTIVE] Patients with chronic kidney disease (CKD) are often underrepresented in clinical trials evaluating the safety profile of newer medication classes for type 2 diabetes (T2D). Given the high burden of comorbidities and polypharmacy in this population, further safety research is needed. This study aimed to detect potential adverse events associated with sodium/glucose cotransporter 2 (SGLT2) inhibitors in patients with T2D and CKD, using a tree-based scan statistic approach. [STUDY DESIGN] New-user active comparator cohort study. [SETTING & PARTICIPANTS] Medicare Fee-for-service data (October 2016 - December 2020) and the Merative MarketScan commercial claims database (October 2016 - December 2022) used to identify patients aged ≥65 years (Medicare) or ≥18 years (MarketScan) with T2D and CKD (Stages III-IV). [EXPOSURES] New use of SGLT2 inhibitors or glucagon-like peptide-1 receptor agonists (GLP-1RA). [OUTCOMES] ICD-10 coded adverse outcome events, in outpatient, inpatient, or emergency department settings. [ANALYTIC APPROACH] After 1:1 propensity-score matching, a hierarchical data-mining surveillance method using ICD-10 outcomes, a tree-based scan statistic, to identify signals for incident adverse events. [RESULTS] We identified 22,328 matched pairs in Medicare (mean age, 74 years; 45% female) and 8,918 matched pairs in MarketScan (mean age, 65 years; 42% female). In both cohorts, based on outpatient diagnosis codes, SGLT2 inhibitor initiation showed safety signals for genital infections in both females and males (p < 0.001). However, the tree-based scan statistic did not detect any safety signals based on inpatient/ED diagnosis codes. [LIMITATIONS] Residual confounding, potential misclassification, and limited power. [CONCLUSIONS] In two large real-world cohorts of patients with T2D and CKD, the tree-based scan statistic identified previously known adverse events, but no new safety signals associated with SGLT2 inhibitor use compared with GLP-1RA use.